Latham BioPharm Group
Latham BioPharm Group is a US life sciences consulting firm providing non-dilutive funding advisory, product development consulting, and strategic consulting services to government agencies, NGOs, and pharmaceutical, biotech, medical device, and animal health companies with a team of approximately 60 consultants.
- Company typePrivate
- Founded1996
- HeadquartersMaynard, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Latham BioPharm Group does
Latham BioPharm Group (LBG) is a US-based life sciences consulting firm founded in 1996 by Peter Latham and headquartered in Frederick, Maryland. The firm provides three core service lines: non-dilutive funding advisory (helping clients secure and manage government and NGO grants from agencies such as BARDA, NIH, and DoD), product development consulting (CMC, regulatory, clinical, nonclinical, discovery, quality, and project management for vaccines, therapeutics, cell and gene therapies, medical devices, diagnostics, and animal health products), and strategic consulting (market research, financial modeling, due diligence, market access, and technology scouting). LBG operates across four sector specializations—LBG Biologics, LBG Pharma, LBG MD&D (Medical Devices, Diagnostics, and Digital Health), and LBG Animal Health—with a team of approximately 60 life sciences consultants.
LBG's revenue model is professional services fee-based, with consulting engagements quoted per project and not publicly disclosed. Clients span US government agencies (BARDA, NIH, DoD components including CDMRP, DARPA, and DTRA), large NGOs and foundations (Bill & Melinda Gates Foundation, CEPI), and commercial pharmaceutical, biotech, medical device, and animal health companies. In October 2022, LBG was acquired by Sia Partners, a global consulting firm, and now operates as Sia's Life Science Consulting division; founder Peter Latham heads the global Life Science division on Sia's Executive Committee. The firm's most notable recent product expansion is the Global Health Cost Model Platform, a web-based pharmaceutical API cost-of-goods modeling tool developed with Bill & Melinda Gates Foundation grant funding.
Latham BioPharm Group firmographics
Firmographics- Name
- Latham BioPharm Group
- Legal name
- Latham BioPharm Group
- Website
- https://lathambiopharm.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Latham BioPharm Group is a US life sciences consulting firm providing non-dilutive funding advisory, product development consulting, and strategic consulting services to government agencies, NGOs, and pharmaceutical, biotech, medical device, and animal health companies with a team of approximately 60 consultants.
- Ownership category
- akta.pro rank
Latham BioPharm Group industry classification
Industry- Product category
- Life Sciences Consulting
- NAICS
- Other Scientific and Technical Consulting Services (54169), Management, Scientific, and Technical Consulting Services (5416)
- SIC
- Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)
- akta.pro secondary industry
- Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)
Keywords
Where Latham BioPharm Group is headquartered
LocationHeadquarters
- HQ city
- Maynard
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Latham BioPharm Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Life Sciences Consulting Services: Professional consulting services including non-dilutive funding support, product development consulting, and strategic consulting. Turnover of nearly $20m as of acquisition in 2022.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Latham BioPharm Group product offering
Product offeringCore offering
Latham BioPharm Group (LBG) provides life sciences consulting services across three core service areas: Non-dilutive Funding Services (government relations, proposal development, post-award support, contract compliance), Product Development Services (CMC, Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, Vendor Management), and Strategic Consulting Services (strategic planning, financial modeling, market research, supply chain optimization, market access, due diligence, technology scouting). The firm supports pharma, biotech, medical device, diagnostic, animal health, and government clients with a team of nearly 60 consultants.
Product overview
Latham BioPharm Group (LBG) provides life sciences consulting services organized into three core service areas: Non-dilutive Funding Services (government relations, proposal development, post-award support, contract compliance), Product Development Services (CMC, Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, Vendor Management), and Strategic Consulting Services (Strategic Planning, Financial Modeling, Market Research, Supply Chain Optimization, Market Access/Launch, Due Diligence, Technology Scouting). The company operates across four sector specializations: LBG Biologics, LBG Animal Health, LBG Pharma, and LBG MD&D (Medical Devices, Diagnostics, and Digital Health). In 2023, LBG launched the Global Health Cost Model Platform, a web-based tool for pharmaceutical API cost analysis developed with Bill & Melinda Gates Foundation funding.
Differentiator
Problem solved
Functional benefit
Products and services
- Non-dilutive Funding Services Consulting services to help life sciences clients secure government and non-governmental funding, including government relations, proposal development, post-award support, and contract compliance. Targets biotech, pharma, and academic organizations seeking non-dilutive funding sources such as BARDA, NIH, and DoD.
- Product Development Services Comprehensive product development support including CMC (Chemistry, Manufacturing, and Controls), Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, and Vendor Management services for vaccines, therapeutics, cell and gene therapies, medical devices, and diagnostics.
- Strategic Consulting Services Consulting services including Strategic Planning, Financial Modeling, Market Research, Supply Chain Network Development & Optimization, Market Access/Launch, Due Diligence, and Technology Scouting for life sciences companies.
- Global Health Cost Model Platform A web-based modeling tool for determining the cost of goods of pharmaceutical APIs (Active Pharmaceutical Ingredients), enabling stakeholders to evaluate the viability and manufacturing approaches of pharmaceutical products for global health access.
Quantifiable outcome
- Led submission of proposals resulting in $400 million in awards
- +3 more outcomes
Companies that use Latham BioPharm Group
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Latham BioPharm Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Latham BioPharm Group partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Bill & Melinda Gates FoundationcoreLBG awarded a grant to develop a web-based modeling tool for calculating pharmaceutical API costs. The tool aims to help stakeholders evaluate the economic viability of pharmaceutical products and manufacturing approaches, supporting global health access.
- Sia PartnerscoreSia Partners acquired Latham BioPharm Group in October 2022, creating a Life Science Consulting division. The acquisition accelerates Sia Partners' growth in the life sciences sector. LBG founder Peter Latham heads the new global Life Science division within Sia Partners' ExCom.
- Alliance for Regenerative Medicine (ARM)minorJim Beltzer contributed to Project A-Cell, a multistakeholder collaboration incorporating Quality by Design principles into CAR-T therapy manufacturing, bringing CMC best practices to cell-based therapy field.
- National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)minorPartnered with NIIMBL on Project A-Cell, contributing expertise to standardize manufacturing methodologies for cell-based therapies.
- Biomedical Advanced Research and Development Authority (BARDA)coreLBG supports clients in securing and managing BARDA contracts. Notable example: Joseph Rininger led a $147 million BARDA contract for Flublok vaccine development.
- BioPharm InternationalminorLBG team members regularly publish articles in BioPharm International magazine on regulatory compliance, FDA 483 observations, and pharmaceutical quality topics.
- New York University (NYU)minorCollaborating with NYU on Smart Diagnostics projects incorporating AI to improve accuracy and clinical utilization of diagnostic tools.
- American Association for Clinical Chemistry (AACC)minorLBG team members attend and network at AACC Annual Scientific Meeting to engage with the global laboratory medicine community.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Latham BioPharm Group competitors and assessment
Company assessmentDirect peers
- ClearView Healthcare Partners: Life sciences strategy consulting firm providing commercial, R&D, and corporate strategy support to biopharma, similar in size and specialty positioning to LBG.
- Trinity Life Sciences: Strategic consulting firm serving pharma and biotech with therapeutic-area strategy, market research, and product development advisory, directly comparable to LBG's strategic consulting and product development practices.
- Putnam Associates: Life sciences-focused consulting firm offering strategic, market access, and product development advisory to pharma/biotech, overlapping directly with LBG's strategic consulting and product development offerings.
- Health Advances: Healthcare and life sciences strategy consulting firm supporting medtech, diagnostics, and biotech clients with commercialization and product development strategy, a closely matched peer in scale and scope.
- Back Bay Life Science Advisors: Boutique life sciences consulting firm providing strategy, market assessment, and product development advisory to biotech and pharma, a close peer in size and specialty orientation to LBG.
Broad incumbents
- ZS Associates: Large global consulting firm with deep pharma/biotech practice spanning strategy, R&D, and commercial, an established incumbent that competes with LBG for pharma advisory engagements.
- LEK Consulting (Life Sciences): Global strategy consulting firm with a sizable life sciences practice offering commercial, R&D, and transaction advisory to pharma and biotech, competing for similar strategic consulting mandates as LBG.
- Charles River Associates (Life Sciences Practice): Global consulting firm with a dedicated Life Sciences practice providing economic, strategic, and regulatory consulting to biopharma, overlapping with LBG on regulatory and strategic work but operating at much larger scale.
- IQVIA (Consulting & Services): Global life sciences services and consulting powerhouse covering R&D strategy, regulatory, and commercial advisory, an incumbent that competes with LBG particularly for CMC, regulatory, and strategic consulting work.
- Parexel International (Consulting): Global CRO with regulatory and product development consulting capabilities that overlap with LBG's CMC and regulatory advisory work, particularly for biotech and government-funded programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Latham BioPharm Group social profiles
Digital presenceLatham BioPharm Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Latham BioPharm Group leadership team
Management profileNumber of profiles
Profiles11 records
Latham BioPharm Group funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Latham BioPharm Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Latham BioPharm Group
What does Latham BioPharm Group do?
Latham BioPharm Group (LBG) provides life sciences consulting services across three core service areas: Non-dilutive Funding Services (government relations, proposal development, post-award support, contract compliance), Product Development Services (CMC, Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, Vendor Management), and Strategic Consulting Services (strategic planning, financial modeling, market research, supply chain optimization, market access, due diligence, technology scouting). The firm supports pharma, biotech, medical device, diagnostic, animal health, and government clients with a team of nearly 60 consultants.
Is Latham BioPharm Group a public or private company?
Latham BioPharm Group is a private company. It is classified as corporate owned and is currently operating.
When was Latham BioPharm Group founded?
Latham BioPharm Group was founded in 1996. It employs 51 to 100 people.
Where is Latham BioPharm Group based?
Latham BioPharm Group is headquartered in Maynard, United States, in the North America region.
How does Latham BioPharm Group make money?
One revenue line is on record: life Sciences Consulting Services.
Who are Latham BioPharm Group's main competitors?
Direct peers on record are ClearView Healthcare Partners, Trinity Life Sciences, Putnam Associates, Health Advances and Back Bay Life Science Advisors. Broad incumbents are ZS Associates, LEK Consulting (Life Sciences), Charles River Associates (Life Sciences Practice), IQVIA (Consulting & Services) and Parexel International (Consulting).
Does Latham BioPharm Group have an API?
No public API is recorded for Latham BioPharm Group.
What industry is Latham BioPharm Group in?
Latham BioPharm Group's product category is Life Sciences Consulting. Its primary akta.pro industry code is HLAGAKAJ, Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA), with a secondary code of HLAGAKAL, Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control). Its NAICS code is 54169 and its SIC code is 8742.